KMT2B and hepatocellular carcinoma: HBV DNA integration into KMT2B is present in 7.70% of HCC tissues and 2.41% of non‐tumour tissues (OR, 3.39; p < .01),49 suggesting a positive selection of cells harbouring HBV integration in KMT2B gene during the development of HCC.